Last reviewed · How we verify
Liraglutide + Exercise training
Liraglutide + Exercise training is a GLP-1 receptor agonist Small molecule drug developed by University of Virginia. It is currently FDA-approved for Type 2 diabetes mellitus (in combination with exercise training), Weight management in obesity (in combination with exercise training).
Liraglutide activates GLP-1 receptors to enhance insulin secretion and reduce appetite, while exercise training improves insulin sensitivity and cardiovascular fitness through physical conditioning.
Liraglutide, a glucagon-like peptide 1 receptor agonist, has been studied in combination with exercise training for conditions such as Type 2 Diabetes, Metabolic Syndrome, and Obesity. The combination of liraglutide and exercise training has been investigated in clinical trials to improve metabolic response in patients with these conditions.
At a glance
| Generic name | Liraglutide + Exercise training |
|---|---|
| Sponsor | University of Virginia |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1, stimulating insulin release in response to glucose and suppressing glucagon secretion, thereby lowering blood glucose. Combined with structured exercise training, which independently improves insulin sensitivity, glucose utilization, and cardiovascular health, this combination approach addresses multiple pathways in metabolic disease management.
Approved indications
- Type 2 diabetes mellitus (in combination with exercise training)
- Weight management in obesity (in combination with exercise training)
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Headache
- Hypoglycemia
Key clinical trials
- Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome (PHASE4)
- Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet (PHASE4)
- The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes (PHASE4)
- Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liraglutide + Exercise training CI brief — competitive landscape report
- Liraglutide + Exercise training updates RSS · CI watch RSS
- University of Virginia portfolio CI
Frequently asked questions about Liraglutide + Exercise training
What is Liraglutide + Exercise training?
How does Liraglutide + Exercise training work?
What is Liraglutide + Exercise training used for?
Who makes Liraglutide + Exercise training?
What drug class is Liraglutide + Exercise training in?
What development phase is Liraglutide + Exercise training in?
What are the side effects of Liraglutide + Exercise training?
What does Liraglutide + Exercise training target?
Related
- Drug class: All GLP-1 receptor agonist drugs
- Target: All drugs targeting GLP-1R
- Manufacturer: University of Virginia — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus (in combination with exercise training)
- Indication: Drugs for Weight management in obesity (in combination with exercise training)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing